Mabpharm Limited (2181.HK)

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People's Republic of China. The company's products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for indications of rheumatoid arthritis, Crohn's disease, etc; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis. In addition, the company's products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab. Further, it is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, chemical biological reagents, diagnostic reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, China. Show more